Navigation Links
Cellectis' Meganuclease Technology Used to Efficiently Prevent Viral Infection
Date:1/19/2011

PARIS, Jan. 19, 2011 /PRNewswire/ -- Cellectis (Alternext: ALCLS), announced today that scientists from Cellectis therapeutics, the French National Center For Medical Research (CNRS) and Institut de la Vision (Paris) have used its proprietary meganucleases to successfully prevent infection of cultured cells by a Herpes Simplex virus (HSV-1). The research has just been published online by Molecular Therapy(1) (Mol. Ther. 2011, Jan 11. Epublication ahead of print).  These are the first proof-of-concept data showing that meganucleases can prevent viral infection.

In this article, scientists used HSV-1 specific meganucleases engineered by Cellectis to successfully prevent the infection of human cultured cells by HSV-1. Subsequent analysis of the treated cells using deep sequencing techniques showed that inhibition of HSV-1 infection by the anti-HSV-1 meganucleases was associated with cleavage of viral DNA (or virus clipping). When the virus is clipped at a well-chosen and specific location, this prevents its normal activity as well as its ability to replicate and spread.

"Virus clipping using meganucleases is a new therapeutic approach to tackle persistent viral infection which could have broad applications in medicine," said Pr. Jose Alain Sahel, Director of Institut de la Vision. "We are particularly interested in the potential of meganucleases in the prevention of recurrent infection during corneal transplantation and look forward to continuing our studies in this area."

"The results published in Molecular Therapy are very exciting since they open new fields of research for fighting HSV recurrent infections, a major cause of both acquired and severe loss of vision," added Dr. Marc Labetoulle, M.D., Ph.D. of CNRS.

About HSV-1 infection

HSV-1 infection is highly prevalent globally, with an estimated 70-90% of the adult population carrying the virus. The majority of seropositive individuals are unaware th
'/>"/>

SOURCE Cellectis therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Monsanto Licenses Use of Cellectis Innovative Genome Modification Technology
2. Cellectis to Present at the American Society of Gene & Cell Therapy Annual Meeting
3. Cellectis to Present at the FASEB Summer Research Conference on Genome Engineering
4. Cellectis bioresearch Establishes The Genome Customization Award (TGCA)
5. Taconics Litigation Contesting License Termination By Cellectis Is Dismissed
6. Cellectis Unveils Its New Corporate Website
7. Cellectis Bioresearch Announces Availability of Research Kits Through New Online E-Store
8. Cellectis Plant Sciences Licenses Plant Transformation Technology From Midwest Oilseeds
9. Cellectis and the Center for iPS Cells Research and Application Enter Collaboration
10. Cellectis Plant Sciences Licenses Plant Transformation Technology for Corn and Rice
11. Cellectis bioresearch Signs Non-Exclusive License With Evrogen for Access to Fluorescent Proteins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. – ... Warrington, Pa. , Details: The Hepatitis B Foundation, ... cure for hepatitis B and improving the quality of life ... on Friday, April 11 at Warrington Country Club in Warrington, ...
(Date:1/14/2014)... January 14, 2014 EquitiesIQ, a leading ... (OTCQB: ALQA). Alliqua is an emerging biomedical company acquiring, ... wound care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... a seasoned management team and Board, which launched the ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation ... developing and commercializing innovative therapies addressing major unmet ... it received the Notice of Allowance from the ... unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment ...
(Date:1/14/2014)... Rochester, NY (PRWEB) January 14, 2014 During ... is now known as “The Doctor’s Plague.” In this time ... their hands. This led, at times, to the death of ... staff today don’t know that they may be unwittingly transmitting ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... HCTL ), today announced unaudited results for the,second quarter ... for the first six months of 2007 were $7.75 million, ... The gross profit for the,first half of the year was ... The net loss for such period was $(319) thousand, versus ...
... 16 Cepheid (Nasdaq:,CPHD) today announced that it ... Northrop Grumman for the purchase of up to ... associated materials. The,anthrax test is currently used in ... Service (USPS) mail processing centers,nationwide. The agreement covers ...
... Topic of Drug Repurposing and ... Indian Clinical Trial Strategy, ... biopharmaceutical company, announced today,that Chief Executive Officer, John Maki, and ... 234th American Chemical,Society National Meeting on Sunday, August 19, 2007. ...
Cached Biology Technology:Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results 2Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results 3Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems 2Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems 3Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA 2Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA 3
(Date:4/23/2014)... found evidence of an interaction between prenatal smoking ... in children, especially in girls. , "The interesting ... prenatal smoking will have behavioral problems. Some ... Assistant Professor at Sam Houston State University, College ... study. "One possible explanation for this is ...
(Date:4/23/2014)... yesterday, Argentina joins the European Molecular Biology Laboratory ... strengthens the ties between the European and Latin ... access to EMBL,s world-class facilities and programs, and ... inception, fostering excellent life science research and promoting ... EMBL,s mission," says EMBL Director General Iain Mattaj ...
(Date:4/23/2014)... coined term for novels and films which focus on the ... shows how these fictions serve as a mental laboratory that ... and imagine other living conditions. , "Global warming is ... it is also a cultural phenomenon in which meaning is ... we see. And there are so many of them now ...
Breaking Biology News(10 mins):Genetics risk, prenatal smoking may predict behavioral problems 2Fiction prepares us for a world changed by global warming 2Fiction prepares us for a world changed by global warming 3
... Life Sciences Discovery Fund (LSDF) today announced its ... will receive life sciences program grants totaling more ... will focus on advancing vaccine development, improving the ... of mental health and substance abuse services in ...
... all a protein needs to do is give quick squeezes ... from The University of Arizona in Tucson. Scientists ... readings of the information coded in the DNA,s sequence. ... called direct readout, can effectively pinpoint sites on DNA using ...
... . , Montreal, December 16, 2008 ... Stephen Michnick is helping the scientific community uncover the ... biochemistry professor and Canada Research Chair in Integrative Genomics, ... him to examine how proteins interact within cells. ...
Cached Biology News:Life Sciences Discovery Fund awards health research program grants 2Life Sciences Discovery Fund awards health research program grants 3Life Sciences Discovery Fund awards health research program grants 4Life Sciences Discovery Fund awards health research program grants 5Just a little squeeze lets proteins assess DNA 2Just a little squeeze lets proteins assess DNA 3Call Stephen Michnick a gene grammarian 2
Goat polyclonal to p27 KIP 1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: C-KRPATDDS STQNK, corresponding to Internal sequence amino acids 153-165 of Human p27 KIP 1 ...
Request Info...
Myt 1 (N-17)...
... are functionally defined by their capacity to ... into multiple specialized progenitor cells, which can ... Neural stem cells (NSCs) are capable of ... neurons and oligodendrocytes. During the isolation and ...
Biology Products: